Flerie AB (publ) (STO:FLERIE)
Sweden · Delayed Price · Currency is SEK 43.20
-0.40 (-0.92%)
Aug 1, 2025, 5:29 PM CET
Flerie AB Company Description
Flerie AB (publ) is a venture capital firm specializing in early-stage investments.
The firm seeks to invest in life science, biotech and pharma companies engaged in drug development and associated tools or applications tackling major medical challenges of our time.
The firm seeks to invest in Europe, United States and Israel. Flerie AB (publ) was founded in 2011 and is based in Stockholm, Sweden with additional office in London, United Kingdom.
Flerie AB (publ)
| Country | Sweden |
| Founded | 2011 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 5 |
| CEO | Ted Fjallman |
Contact Details
Address: Skeppsbron 16 Stockholm, 111 30 Sweden | |
| Phone | 46 (0)76 131 01 27 |
| Website | flerie.com |
Stock Details
| Ticker Symbol | FLERIE |
| Exchange | Nasdaq Stockholm |
| Fiscal Year | January - December |
| Reporting Currency | SEK |
| ISIN Number | SE0008966295 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Cecilia Stureborg von Schéele | Chief Financial Officer and Deputy Chief Executive Officer |
| Dr. Ted Fjallman Ph.D. | Chief Executive Officer |
| Thomas Eldered M.Sc., MSc | Executive Chairman of the Board |
| Paula Andersson | Operations and Investor Relations Manager |
| Mark Quick | Partner |
| Karl Elmqvist | Investment Manager |
| Dr. Carl-Johan Spak Ph.D. | Senior Advisor |
| Carlos von Bonhorst M.D. | Senior Advisor |
| Michaela Gertz | Senior Advisor |